$BPMC
Blueprint Medicines Corp

2021 Q4 Form 10-Q Financial Statement

#000155837021013719 Filed on October 28, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $107.0M $24.19M $745.1M
YoY Change 213.84% -96.75% 8053.17%
Cost Of Revenue $7.549M $3.790M $146.0K
YoY Change 7449.0% 2495.89%
Gross Profit $99.47M $20.40M $745.0M
YoY Change 192.56% -97.26%
Gross Profit Margin 92.95% 84.33% 99.98%
Selling, General & Admin $54.20M $49.81M $37.38M
YoY Change 27.53% 33.26% 45.73%
% of Gross Profit 54.49% 244.17% 5.02%
Research & Development $356.9M $84.42M $74.23M
YoY Change 361.08% 13.73% -8.87%
% of Gross Profit 358.77% 413.86% 9.96%
Depreciation & Amortization $1.663M $1.616M $1.600M
YoY Change -2.18% 1.0% 23.08%
% of Gross Profit 1.67% 7.92% 0.21%
Operating Expenses $415.6M $134.2M $111.6M
YoY Change 246.34% 20.27% 4.21%
Operating Profit -$316.1M -$113.8M $633.4M
YoY Change 267.6% -117.97%
Interest Expense $463.0K $552.0K $1.200M
YoY Change -48.56% -54.0%
% of Operating Profit 0.19%
Other Income/Expense, Net -$380.0K $30.00K $981.0K
YoY Change -480.0% -96.94% -73.39%
Pretax Income -$316.1M -$117.1M $634.3M
YoY Change 271.83% -118.45% -772.87%
Income Tax $2.633M $175.0K $370.0K
% Of Pretax Income 0.06%
Net Earnings -$318.7M -$117.2M $634.0M
YoY Change 271.86% -118.49% -772.48%
Net Earnings / Revenue -297.78% -484.71% 85.08%
Basic Earnings Per Share -$2.00 $11.49
Diluted Earnings Per Share -$5.402M -$2.00 $11.16
COMMON SHARES
Basic Shares Outstanding 58.84M 58.65M 55.17M
Diluted Shares Outstanding 58.65M 56.79M

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $477.1M $701.9M $757.4M
YoY Change -45.28% -7.33% 53.5%
Cash & Equivalents $209.9M $553.6M $565.2M
Short-Term Investments $267.2M $148.3M $192.2M
Other Short-Term Assets $18.06M $23.68M $17.40M
YoY Change -17.89% 36.07% 14.47%
Inventory $21.82M $16.57M $5.565M
Prepaid Expenses
Receivables $25.16M $18.40M $44.37M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $554.0M $771.8M $841.7M
YoY Change -40.28% -8.29% 63.83%
LONG-TERM ASSETS
Property, Plant & Equipment $30.70M $31.20M $35.20M
YoY Change -10.05% -11.35% -8.12%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $557.5M $591.9M $598.5M
YoY Change -17.76% -1.1% 492.57%
Other Assets $14.64M $14.19M $8.666M
YoY Change 147.05% 63.78% 50.95%
Total Long-Term Assets $698.2M $705.5M $716.5M
YoY Change -11.69% -1.54% 219.59%
TOTAL ASSETS
Total Short-Term Assets $554.0M $771.8M $841.7M
Total Long-Term Assets $698.2M $705.5M $716.5M
Total Assets $1.252B $1.477B $1.558B
YoY Change -27.13% -5.19% 111.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.333M $9.549M $2.929M
YoY Change 90.69% 226.02% 32.96%
Accrued Expenses $121.8M $94.54M $89.12M
YoY Change 15.0% 6.09% 10.81%
Deferred Revenue $11.51M $6.792M $10.39M
YoY Change -8.35% -34.64% 110.64%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $149.8M $119.7M $110.1M
YoY Change 14.5% 8.7% 16.96%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $3.344M $6.885M $9.318M
YoY Change -53.78% -26.11% 7665.0%
Total Long-Term Liabilities $3.344M $6.885M $9.318M
YoY Change -53.78% -26.11% 7665.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $149.8M $119.7M $110.1M
Total Long-Term Liabilities $3.344M $6.885M $9.318M
Total Liabilities $281.5M $230.2M $238.2M
YoY Change 13.36% -3.33% 7.49%
SHAREHOLDERS EQUITY
Retained Earnings -$1.275B -$956.8M -$545.7M
YoY Change 102.02% 75.33% -37.91%
Common Stock $59.00K $59.00K $56.00K
YoY Change 1.72% 5.36% 14.29%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $970.7M $1.247B $1.320B
YoY Change
Total Liabilities & Shareholders Equity $1.252B $1.477B $1.558B
YoY Change -27.13% -5.19% 111.16%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$318.7M -$117.2M $634.0M
YoY Change 271.86% -118.49% -772.48%
Depreciation, Depletion And Amortization $1.663M $1.616M $1.600M
YoY Change -2.18% 1.0% 23.08%
Cash From Operating Activities -$14.11M -$95.60M $622.3M
YoY Change -43.09% -115.36% -967.92%
INVESTING ACTIVITIES
Capital Expenditures -$1.258M -$996.0K $0.00
YoY Change 79.71% -100.0%
Acquisitions
YoY Change
Other Investing Activities -$345.7M $105.1M -$430.1M
YoY Change 361.54% -124.43% -632.96%
Cash From Investing Activities -$347.0M $104.1M -$430.1M
YoY Change 359.54% -124.2% -677.32%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 17.93M 10.92M 84.40M
YoY Change -91.85% -87.06% 1775.56%
NET CHANGE
Cash From Operating Activities -14.11M -95.60M 622.3M
Cash From Investing Activities -347.0M 104.1M -430.1M
Cash From Financing Activities 17.93M 10.92M 84.40M
Net Change In Cash -343.1M 19.40M 276.6M
YoY Change -386.43% -92.99% 3689.04%
FREE CASH FLOW
Cash From Operating Activities -$14.11M -$95.60M $622.3M
Capital Expenditures -$1.258M -$996.0K $0.00
Free Cash Flow -$12.86M -$94.60M $622.3M
YoY Change -46.66% -115.2% -1050.08%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q3 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
CY2020Q4 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
57793533
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
57793533
CY2021Q3 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0
us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0
CY2021Q3 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2020Q3 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-117241000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
633978000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-325399000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
399550000
dei Entity Central Index Key
EntityCentralIndexKey
0001597264
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37359
dei Entity Registrant Name
EntityRegistrantName
BLUEPRINT MEDICINES CORPORATION
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-3632015
dei Entity Address Address Line1
EntityAddressAddressLine1
45 Sidney Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02139
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
374-7580
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
dei Security12b Title
Security12bTitle
Common stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
BPMC
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Listing Par Value Per Share
EntityListingParValuePerShare
0.001
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
58838034
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
553593000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
684636000
CY2021Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
148285000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
187213000
CY2021Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
18400000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
7096000
CY2021Q3 bpmc Unbilled Receivables Including Reimbursable Costs Current
UnbilledReceivablesIncludingReimbursableCostsCurrent
11324000
CY2020Q4 bpmc Unbilled Receivables Including Reimbursable Costs Current
UnbilledReceivablesIncludingReimbursableCostsCurrent
18213000
CY2021Q3 us-gaap Inventory Net
InventoryNet
16570000
CY2020Q4 us-gaap Inventory Net
InventoryNet
8581000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
23676000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
22020000
CY2021Q3 us-gaap Assets Current
AssetsCurrent
771848000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
927759000
CY2021Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
591920000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
677873000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
31204000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
34129000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
62986000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
67539000
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5171000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5168000
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
14193000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5925000
CY2021Q3 us-gaap Assets
Assets
1477322000
CY2020Q4 us-gaap Assets
Assets
1718393000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
9549000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4370000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
94540000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
105938000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
8810000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
7935000
CY2021Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
6792000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
12559000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
119691000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
130802000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
75054000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
81669000
CY2021Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
28605000
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
28599000
CY2021Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
6885000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
7235000
CY2021Q3 us-gaap Liabilities
Liabilities
230235000
CY2020Q4 us-gaap Liabilities
Liabilities
248305000
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
58814666
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
57793533
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
59000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
58000
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2209456000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2106600000
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5673000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5214000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-956755000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-631356000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
1247087000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
1470088000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1477322000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1718393000
CY2021Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
24188000
CY2020Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
745118000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
73059000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
759629000
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3790000
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
146000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
10385000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
297000
CY2021Q3 bpmc Collaboration Profit Loss Sharing
CollaborationProfitLossSharing
3269000
bpmc Collaboration Profit Loss Sharing
CollaborationProfitLossSharing
3269000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
84419000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
74230000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
244157000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
249456000
CY2021Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
49806000
CY2020Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
37375000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
141093000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
115203000
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
141284000
CY2020Q3 us-gaap Costs And Expenses
CostsAndExpenses
111751000
us-gaap Costs And Expenses
CostsAndExpenses
398904000
us-gaap Costs And Expenses
CostsAndExpenses
364956000
CY2021Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
552000
CY2020Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
1173000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
1923000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
5663000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-522000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-192000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1109000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-416000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
30000
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
981000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
814000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5247000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-117066000
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
634348000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-325031000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
399920000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
175000
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
370000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
368000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
370000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-117241000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
633978000
us-gaap Net Income Loss
NetIncomeLoss
-325399000
us-gaap Net Income Loss
NetIncomeLoss
399550000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-12000
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-777000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1035000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
658000
CY2021Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
174000
CY2020Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-43000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
577000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-64000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-117079000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
633158000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-325857000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
400144000
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.00
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
11.49
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.58
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
7.40
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.00
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
11.16
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.58
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
7.20
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58647000
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55169000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58361000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54018000
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58647000
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56786000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58361000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55492000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
1470088000
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
8318000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
21212000
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
117000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-99714000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
1400021000
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
11710000
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1733000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
24522000
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-738000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-108444000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
1328804000
CY2021Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
11038000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
24324000
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
162000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-117241000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
1247087000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
464359000
CY2020Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1613000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
17026000
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
308423000
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
2465000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-110953000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
682933000
CY2020Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2335000
CY2020Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
942000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
19675000
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1051000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-123474000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
7000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
581367000
CY2020Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
6280000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
19889000
CY2020Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
79306000
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-820000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
633978000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
1320000000
us-gaap Profit Loss
ProfitLoss
-325399000
us-gaap Profit Loss
ProfitLoss
399550000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4816000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4887000
bpmc Lease Right Of Use Asset Amortization
LeaseRightOfUseAssetAmortization
4668000
bpmc Lease Right Of Use Asset Amortization
LeaseRightOfUseAssetAmortization
4289000
us-gaap Share Based Compensation
ShareBasedCompensation
68949000
us-gaap Share Based Compensation
ShareBasedCompensation
56022000
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
2677000
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
573000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
11375000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
43705000
bpmc Increase Decrease In Customer Assets
IncreaseDecreaseInCustomerAssets
-6891000
bpmc Increase Decrease In Customer Assets
IncreaseDecreaseInCustomerAssets
-5862000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
11812000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
4491000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1795000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
7266000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
2842000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-1796000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
5144000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1978000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-12844000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1573000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-5761000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-666000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-5856000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-4612000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-284539000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
411834000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1831000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2472000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
514906000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
796980000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
637831000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
440735000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
121094000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-358717000
bpmc Proceeds From Issuance Of Common Stock Net Of Underwriting Discounts Commissions And Offering Expenses
ProceedsFromIssuanceOfCommonStockNetOfUnderwritingDiscountsCommissionsAndOfferingExpenses
308750000
bpmc Net Proceeds From Stock Option Exercises And Employee Stock Purchase Plan
NetProceedsFromStockOptionExercisesAndEmployeeStockPurchasePlan
32787000
bpmc Net Proceeds From Stock Option Exercises And Employee Stock Purchase Plan
NetProceedsFromStockOptionExercisesAndEmployeeStockPurchasePlan
9921000
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
79305000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
310000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
32787000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
397666000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-130658000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
450783000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
689804000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
119604000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-382000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
558764000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
206000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
570389000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
209000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
674000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
68000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
553593000
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
565221000
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5171000
CY2020Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5168000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
558764000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
570389000
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1. Nature of Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Blueprint Medicines Corporation (the Company), a Delaware corporation incorporated on October 14, 2008, is a precision therapy company focused on genomically defined cancers and hematologic disorders. The Company’s approach is to leverage its novel target discovery engine to systematically and reproducibly identify kinases that are drivers of diseases and to craft highly selective and potent drugs and drug candidates that may provide significant and durable clinical responses for patients without adequate treatment options. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has two approved precision therapies and is globally advancing multiple programs for genomically defined cancers, systemic mastocytosis, and cancer immunotherapy. The Company is devoting substantially all of its efforts to research and development for current and future drug candidates and commercialization of AYVAKIT/AYVAKYT, GAVRETO and any current or future drug candidates that obtain marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of September 30, 2021, the Company had cash, cash equivalents and marketable securities of $1,293.8 million. Based on the Company’s current operating plans, the Company anticipates that its existing cash, cash equivalents and marketable securities will <span style="background-color:#ffffff;color:#212529;">be sufficient to enable it to fund its current operations for at least the next twelve months from the issuance of the financial statements. </span></p>
CY2021Q3 us-gaap Investments And Cash
InvestmentsAndCash
1293800000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and in developing the estimates and assumptions that are used in the preparation of the financial statements. Management must apply significant judgment in this process. Management’s estimation process often may yield a range of potentially reasonable estimates and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: revenue recognition, inventory, operating lease right-of-use assets, operating lease liabilities, stock-based compensation expense, accrued expenses, and income taxes. The length of time and full extent to which the ongoing COVID-19 pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, including revenues, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, subject to change and difficult to predict, including as a result of new information that may emerge concerning COVID-19, including the identification and spread of new variants, and the actions taken to contain or treat COVID-19, as well as the economic impact thereof on local, regional, national and international customers and markets. The Company considers the impact of COVID-19 while making the estimates within its consolidated financial statements and there may be changes to those estimates in future periods. Actual results may differ from these estimates.</p>
CY2021Q3 us-gaap Debt Securities Available For Sale Amortized Cost After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
740279000
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
168000
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
242000
CY2021Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
740205000
CY2020Q4 us-gaap Debt Securities Available For Sale Amortized Cost After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
864138000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
962000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
14000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
865086000
CY2021Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
38
CY2021Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
407200000
CY2020Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
8
CY2020Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
125700000
CY2021Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0
CY2020Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0
CY2021Q3 bpmc Debt Securities Available For Sale Number Of Positions
DebtSecuritiesAvailableForSaleNumberOfPositions
53
CY2021Q3 us-gaap Available For Sale Securities Debt Maturities Rolling Year Two Through Five Fair Value
AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue
591900000
CY2020Q4 bpmc Debt Securities Available For Sale Number Of Positions
DebtSecuritiesAvailableForSaleNumberOfPositions
65
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities Rolling Year Two Through Five Fair Value
AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue
677900000
CY2021Q3 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
237300000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
637800000
CY2020Q3 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
134700000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
440700000
CY2020Q4 us-gaap Contract With Customer Asset Accumulated Allowance For Credit Loss
ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
1192000
us-gaap Contract With Customer Asset Credit Loss Expense
ContractWithCustomerAssetCreditLossExpense
5665000
us-gaap Contract With Customer Asset Allowance For Credit Loss Recovery
ContractWithCustomerAssetAllowanceForCreditLossRecovery
3416000
CY2021Q3 us-gaap Contract With Customer Asset Accumulated Allowance For Credit Loss
ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
3441000
CY2021Q3 us-gaap Contract With Customer Asset Accumulated Allowance For Credit Loss
ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
3441000
CY2020Q4 us-gaap Contract With Customer Asset Accumulated Allowance For Credit Loss
ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
1192000
CY2021Q3 bpmc Inventory Current And Noncurrent Raw Materials Net Of Reserves
InventoryCurrentAndNoncurrentRawMaterialsNetOfReserves
3384000
CY2021Q3 bpmc Inventory Current And Noncurrent Work In Process Net Of Reserves
InventoryCurrentAndNoncurrentWorkInProcessNetOfReserves
17841000
CY2020Q4 bpmc Inventory Current And Noncurrent Work In Process Net Of Reserves
InventoryCurrentAndNoncurrentWorkInProcessNetOfReserves
9488000
CY2021Q3 bpmc Inventory Current And Noncurrent Finished Goods Net Of Reserves
InventoryCurrentAndNoncurrentFinishedGoodsNetOfReserves
4415000
CY2020Q4 bpmc Inventory Current And Noncurrent Finished Goods Net Of Reserves
InventoryCurrentAndNoncurrentFinishedGoodsNetOfReserves
914000
CY2021Q3 bpmc Inventory Current And Noncurrent Net
InventoryCurrentAndNoncurrentNet
25640000
CY2020Q4 bpmc Inventory Current And Noncurrent Net
InventoryCurrentAndNoncurrentNet
10402000
CY2021Q3 us-gaap Inventory Net
InventoryNet
16570000
CY2020Q4 us-gaap Inventory Net
InventoryNet
8581000
CY2021Q3 us-gaap Inventory Noncurrent
InventoryNoncurrent
9070000
CY2020Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
1821000
CY2021Q3 bpmc Inventory Current And Noncurrent Net
InventoryCurrentAndNoncurrentNet
25640000
CY2020Q4 bpmc Inventory Current And Noncurrent Net
InventoryCurrentAndNoncurrentNet
10402000
CY2021Q3 us-gaap Inventory Write Down
InventoryWriteDown
400000
us-gaap Inventory Write Down
InventoryWriteDown
800000
CY2020Q3 us-gaap Inventory Write Down
InventoryWriteDown
0
us-gaap Inventory Write Down
InventoryWriteDown
0
CY2021Q3 us-gaap Restricted Cash
RestrictedCash
5200000
CY2020Q4 us-gaap Restricted Cash
RestrictedCash
5200000
CY2021Q3 bpmc External Research Development And Commercial Contract Costs Current
ExternalResearchDevelopmentAndCommercialContractCostsCurrent
49714000
CY2020Q4 bpmc External Research Development And Commercial Contract Costs Current
ExternalResearchDevelopmentAndCommercialContractCostsCurrent
60255000
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
22327000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
27622000
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
13258000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
10986000
CY2021Q3 bpmc Accrued Contract With Customer Asset Accumulated Allowance For Credit Loss
AccruedContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
2939000
CY2020Q4 bpmc Accrued Contract With Customer Asset Accumulated Allowance For Credit Loss
AccruedContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
966000
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
6302000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
6109000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
94540000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
105938000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6030639
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
61.28
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1006635
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
98.10
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
703398
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
44.16
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Other Increases Decreases In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod
375402
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Other Share Increase Decrease In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice
79.21
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5958474
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
68.39
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
3474564
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
59.44
CY2021Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
106600000
CY2021Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y5M23D
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
24000000.0
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
68900000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
19600000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
56000000.0
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
24324000
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
19889000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
70058000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
56590000
CY2021Q3 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
366000
CY2020Q3 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
254000
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
1109000
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
568000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
23958000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
19635000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
68949000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
56022000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
23958000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
19635000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
68949000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
56022000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-117241000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
633978000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-325399000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
399550000
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58647000
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55169000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58361000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54018000
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58647000
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56786000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58361000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55492000
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.00
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
11.49
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.58
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
7.40
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.00
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
11.16
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.58
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
7.20
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7520000
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4730000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7520000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4637000
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
4676000
CY2020Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
4303000
us-gaap Operating Lease Cost
OperatingLeaseCost
13861000
us-gaap Operating Lease Cost
OperatingLeaseCost
13014000
CY2021Q3 us-gaap Sublease Income
SubleaseIncome
838000
CY2020Q3 us-gaap Sublease Income
SubleaseIncome
730000
us-gaap Sublease Income
SubleaseIncome
1434000
us-gaap Sublease Income
SubleaseIncome
2181000
CY2021Q3 us-gaap Lease Cost
LeaseCost
3838000
CY2020Q3 us-gaap Lease Cost
LeaseCost
3573000
us-gaap Lease Cost
LeaseCost
12427000
us-gaap Lease Cost
LeaseCost
10833000
us-gaap Operating Lease Payments
OperatingLeasePayments
11121000
us-gaap Operating Lease Payments
OperatingLeasePayments
10789000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
141000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
486000
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y9M18D
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.082

Files In Submission

Name View Source Status
0001558370-21-013719-index-headers.html Edgar Link pending
0001558370-21-013719-index.html Edgar Link pending
0001558370-21-013719.txt Edgar Link pending
0001558370-21-013719-xbrl.zip Edgar Link pending
bpmc-20210930.xsd Edgar Link pending
bpmc-20210930x10q.htm Edgar Link pending
bpmc-20210930x10q_htm.xml Edgar Link completed
bpmc-20210930xex31d1.htm Edgar Link pending
bpmc-20210930xex31d2.htm Edgar Link pending
bpmc-20210930xex32d1.htm Edgar Link pending
bpmc-20210930_cal.xml Edgar Link unprocessable
bpmc-20210930_def.xml Edgar Link unprocessable
bpmc-20210930_lab.xml Edgar Link unprocessable
bpmc-20210930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending